ISR Biomarker Panel: Tissue-Specific Integrated Stress Response Readouts
The ISR/GCN2βATF4 pathway is mechanistically implicated in ME/CFS pathophysiology (Chapter:energy-metabolism, Section:isr-context-dependence), but the tissue compartmentalisation hypothesis (Tissue Compartmentalization Explains ISR Biomarker Failure in ME/CFS) predicts that blood-based ISR markers will be uninformative. This section describes ISR biomarkers ranging from clinically accessible serum analytes to research-stage tissue assays.
1 Tissue ISR Panel (Muscle Biopsy)
2 HHV-6 miR-aU14 Plasma Exosome Assay
3 Functional PBMC ISR Challenge Assay
4 Additional ISR Biomarker Candidates
Skin biopsy for intraepidermal nerve fibre density (IENFD) is already in clinical use for small-fibre neuropathy (SFN) diagnosis in ME/CFS. DRG sensory neurons projecting to skin are a likely ISR-affected compartment ([NO SPECULATION] if validated). A combined three-marker skin biopsy β (a) IENFD (SFN quantification), (b) ATF4 immunohistochemistry in dermal fibroblasts and perivascular cells, (c) mast cell tryptase density β would provide a multi-mechanism tissue readout from a single 3mm punch biopsy.
Advantages: Minimally invasive; skin is accessible; existing SFN biopsy infrastructure can be extended. ATF4 IHC protocols are established in cancer pathology. Mast cell quantification provides the MCAS overlap readout simultaneously.
What would be needed: ATF4 antibody validation in normal human skin fibroblasts; reference range development in healthy controls; correlation study with muscle biopsy ISR panel to establish skin as a surrogate tissue. Certainty: 0.40 β technically feasible extension of existing protocols; correlation with muscle ISR unknown.
The Omdal null result establishes that baseline PBMC ISR markers are uninformative. However, the dynamics of ISR resolution may still differ. A functional assay would expose PBMCs to acute ER stressor (thapsigargin 200 nM, 30 min, then washout) and measure phospho-eIF2Ξ± kinetics over 0β6 hours.
If GADD34/PP1 dephosphorylation is impaired in ME/CFS (PEM as Biphasic ISR Cycle: Adaptive Initiation and Maladaptive Persistence), PBMCs may show delayed resolution even with identical baselines β converting a null static biomarker into a positive functional biomarker. Most valuable as a pharmacodynamic surrogate endpoint in ISR-modulating drug trials rather than as a diagnostic test. (Certainty of positive result: 0.40.)
Certainty: 0.45. FGF21 (fibroblast growth factor 21) is a second canonical ATF4 target secreted by liver and muscle, also responsive to ISR activation GDF15/FGF21 ratio may offer greater ISR-specificity than either alone: FGF21 also responds to ketogenic state, prolonged exercise, and fasting independently of ISR, while GDF15 is more specifically driven by mitochondrial stress. A GDF15/FGF21 ratio elevated above fasting-exercise baseline would implicate ISR specifically.
Testable prediction: GDF15/FGF21 ratio is elevated in ME/CFS patients versus sedentary controls after controlling for BMI, age, fasting state, and activity. The ratio rises and returns to (elevated) baseline in healthy controls within 24 hours post-CPET; ME/CFS patients show persistent ratio elevation at 48 hours. This ratio constitutes a pharmacodynamic endpoint for ISR-modulating interventions.
Limitation: GDF15/FGF21 ratio has not been validated as an ISR index in any human study. Ratio variability depends on metabolic state; standardised fasting conditions are required. (Not yet replicated.)